Impel Pharmaceuticals LLC
$15.8K 1,000 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Stereotaxis Inc
Stereotaxis Inc reported $15,710.58 across General Payments, Research, and Ownership to 180 physicians and teaching hospitals across 180 transactions.
- $15.7K Below-median payer
- All-tracks total
- 180 Above-median volume
- Transactions
- 180 Above-median reach
- Recipients
- −$35.8K
- General Payments vs PY2023
Stereotaxis Inc reported $15,710.58 across all CMS Open Payments tracks (General + Research + Ownership) to 180 physicians and teaching hospitals in Program Year 2024 - ranking #1571 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $15,710.58, averaging $87.28 per recipient.
Stereotaxis Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer stereotaxis-inc Stereotaxis Inc
$15.7K · #1571/1,925 · 0.0% industry · PY2024
- TOT $15.7K
- RANK #1571
- SHARE 0.0%
- TXN 180
- RCP 180
- CAT 2
- GEN $15.7K
- ΔGEN −$35.8K
- TOP1 15.0%
- PY 2024
Volume peers
Nearest volume peer: Impel Pharmaceuticals LLC ($15.8K)
Stereotaxis Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Stereotaxis Inc's CMS-reported General Payments decreased by $35.8K (−69.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: STEREOTAXIS INCPY2023: STEREOTAXIS INCPY2024: Stereotaxis Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $51,560.45
- PY2024
- $15,710.58
What the Data Shows for Stereotaxis Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Stereotaxis Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Travel and Lodging" leads the 2-category general-payment breakdown below at $10.0K (63.7% of General Payments, 36 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Stereotaxis Inc made 2 types of general payments. "Travel and Lodging" is the largest category at $10.0K, 63.7% of General Payments.
How Stereotaxis Inc divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $10.0K | 36 | 63.7% |
| Entertainment | $5.7K | 144 | 36.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $7,819.25 (49.8%) of $15,710.58 in this company's General Payments records across 51 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Stereotaxis Inc
The five named recipients with the highest reported General Payments from this company
- 1
Nathaniel David McConkey
$2,352.84 across 6 reported transactions
- 2
Matthew Hakimi
$1,906.24 across 13 reported transactions
- 3
William Gionfriddo
$1,427.98 across 14 reported transactions
- 4
Raghuveer Dendi
$1,141.63 across 6 reported transactions
- 5
Bradley M Bacik
$990.56 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Stereotaxis Inc ranks #1571 of 1,925 by total payments (bottom 18% by spend) but is notably more concentrated than that alone would suggest -- #1,182 of 1,838 by HHI (bottom 36% least concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Ascendis Pharma Inc : $470.4K total payments, HHI 686
- Distalmotion US : $620.2K total payments, HHI 685
- Maxx Orthopedics, Inc. : $96.6K total payments, HHI 683
- Janssen Scientific Affairs, LLC : $5.7M total payments, HHI 681
- Dentsply Sirona Inc : $10.4M total payments, HHI 679
- Swedish Orphan Biovitrum Ab : $276.4K total payments, HHI 679
- Stereotaxis Inc (this company) : $15.7K total payments, HHI 679
- TheracosBio, LLC : $7.4K total payments, HHI 674
- Keystone Dental Inc. : $492.7K total payments, HHI 673
- Roche Diabetes Care, Inc. : $9.1K total payments, HHI 672
- EvoEndo, Inc : $57.2K total payments, HHI 667
- Nexus Medical Technologies Llc : $4.1K total payments, HHI 667
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Stereotaxis Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Stereotaxis Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Stereotaxis Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Hoya Surgical Optics GmbH
$15.9K 3 recipients
Compare payment profiles
Monaghan Medical Corporation
$16.0K 224 recipients
Compare payment profiles
Great Lakes Medical Services, LLC
$15.4K 35 recipients
Compare payment profiles
Gebauer Company
$15.3K 12 recipients
Compare payment profiles
Zentech Inc.
$15.2K 12 recipients
Compare payment profiles
Put this to use
Stereotaxis Inc ranks #1571 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Stereotaxis Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.